Orano Med SACancerOrano Med and Roche ink clincical distribution deal in radiopharmacyOrano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production … more ➔
fvm.dkAgri-biotechEU trilogue sets clear path for new genomic techniquesAfter four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules … more ➔
Office of Congresswoman Ayanna Pressley - https://pressley.house.gov/press-kit/Hair lossTopical DHT blockade demonstrates significant efficacyClascoterone 5% topical solution has demonstrated significant hair growth in Phase III trials, showing strong efficacy and a favourable safety profile in men with androgenetic alopecia. more ➔
gov.ukPharma tariffsUK hikes drug prices after pharma exodusAfter the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed … more ➔
EIB, Oscar RomanoFinancing/PartneringAngelini Ventures and EIB launch joint start-up financingThe European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support … more ➔
adobe.stock.com - CathyIndustrial BiotechEU Commission presents new bioeconomy strategyA month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be … more ➔
Afyren GroupBioeconomy€ 23 Mio: Afyren successful in capital increaseFrench Afyren secures €23m to accelerate biorefinery expansion as first plant enters full industrial ramp-up. Most of the money comes from US company Kemin Industries. more ➔
freshidea / Adobe StockImmuno-oncologyVentuno Biotech Secures €3m to Power Next-Gen Cancer ImmunotherapiesLyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets. more ➔
adobe.stock.com - ipopbaAlzheimer'sNovo Nordisk’s semaglutide fails in Alzheimer’sNovo Nordisk’s semaglutide has failed to reduce the cognition deficit in two Phase III Alzheimer’s trials, dimming GLP-1 hopes. Anti-amyloid and combination therapies remain key for slowing decl … more ➔
Gilead ScienceDealGilead acquires Sprint Bioscience TREX1 programmeSprint Bioscience AB has sold its preclinical TREX1 first-in-class cancer program to Gilead for up to US$414m, validating its fragment-driven small-molecule out-licensing business model. more ➔
Orano Med SA
fvm.dk
Office of Congresswoman Ayanna Pressley - https://pressley.house.gov/press-kit/
gov.uk
EIB, Oscar Romano
adobe.stock.com - Cathy
Afyren Group
freshidea / Adobe Stock
adobe.stock.com - ipopba
Gilead Science